title: mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.
authors.forename: Heinz-Josef
authors.initials: HJ
authors.lastname: Klümpen
authors.forename: Karla C S
authors.initials: KC
authors.lastname: Queiroz
authors.forename: C Arnold
authors.initials: CA
authors.lastname: Spek
authors.forename: Carel J M
authors.initials: CJ
authors.lastname: van Noesel
authors.forename: Helmy C
authors.initials: HC
authors.lastname: Brink
authors.forename: Wendy W J
authors.initials: WW
authors.lastname: de Leng
authors.forename: Roeland F
authors.initials: RF
authors.lastname: de Wilde
authors.forename: Elisabeth M H
authors.initials: EM
authors.lastname: Mathus-Vliegen
authors.forename: G Johan A
authors.initials: GJ
authors.lastname: Offerhaus
authors.forename: Maarten A
authors.initials: MA
authors.lastname: Alleman
authors.forename: Anneke M
authors.initials: AM
authors.lastname: Westermann
authors.forename: Dirk J
authors.initials: DJ
authors.lastname: Richel
mesh_terms: D000091162:AMP-Activated Protein Kinase Kinases; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001483:Base Sequence; D000068338:Everolimus; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics; D010580:Peutz-Jeghers Syndrome / Q000150:complications / Q000235:genetics; D017346:Protein Serine-Threonine Kinases / Q000235:genetics; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus; C546842:MTOR protein, human; D017346:Protein Serine-Threonine Kinases; C109790:STK11 protein, human; D058570:TOR Serine-Threonine Kinases; D000091162:AMP-Activated Protein Kinase Kinases; D020123:Sirolimus